Assuming that inhibition of IRAK1 activity might relieve inflammation in lupus mouse models, we studied the lipopolysaccharide (LPS)-induced splenocytes, CD4+ T lymphocytes, and pathological symptoms of MRL/lpr mice. Here, IRAK1 is linked to systemic lupus erythematosus.